Literature DB >> 20059332

Heparin-induced thrombocytopenia.

Gowthami M Arepally1, Thomas L Ortel.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune-mediated hypercoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin. HIT develops in temporal association with heparin therapy and manifests either as an unexplained thrombocytopenia or thrombocytopenia complicated by thrombosis. The propensity for thrombosis distinguishes HIT from other common drug-induced thrombocytopenias. Diagnosing HIT in hospitalized patients is often challenging because of the frequency of heparin use, occurrence of thrombocytopenia from other causes, and development of asymptomatic PF4/heparin antibodies in patients treated with heparin. This review summarizes our current understanding of the pathogenesis, clinical features, diagnostic criteria, and management approaches in HIT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20059332      PMCID: PMC4153429          DOI: 10.1146/annurev.med.042808.171814

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  74 in total

1.  Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia.

Authors:  B Tardy; B Tardy-Poncet; P Fournel; C Venet; R Jospe; A Dacosta
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

2.  Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.

Authors:  J I Zwicker; L Uhl; W-Y Huang; B H Shaz; K A Bauer
Journal:  J Thromb Haemost       Date:  2004-12       Impact factor: 5.824

3.  Thrombocytopenia in a surgical ICU.

Authors:  F Stéphan; J Hollande; O Richard; A Cheffi; M Maier-Redelsperger; A Flahault
Journal:  Chest       Date:  1999-05       Impact factor: 9.410

4.  Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia.

Authors:  C Pouplard; J Amiral; J Y Borg; S Laporte-Simitsidis; B Delahousse; Y Gruel
Journal:  Am J Clin Pathol       Date:  1999-05       Impact factor: 2.493

5.  Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.

Authors:  D E Wallis; D L Workman; B E Lewis; L Steen; R Pifarre; J F Moran
Journal:  Am J Med       Date:  1999-06       Impact factor: 4.965

6.  Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass.

Authors:  A Lillo-Le Louët; P Boutouyrie; M Alhenc-Gelas; C Le Beller; I Gautier; M Aiach; D Lasne
Journal:  J Thromb Haemost       Date:  2004-11       Impact factor: 5.824

7.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

8.  False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus.

Authors:  R Pauzner; A Greinacher; K Selleng; K Althaus; B Shenkman; U Seligsohn
Journal:  J Thromb Haemost       Date:  2009-03-05       Impact factor: 5.824

9.  Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia.

Authors:  T Bakchoul; A Giptner; A Najaoui; G Bein; S Santoso; U J H Sachs
Journal:  J Thromb Haemost       Date:  2009-04-30       Impact factor: 5.824

10.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

View more
  25 in total

1.  [Unusual intensive care course in a patient with head injuries].

Authors:  M D'Anastasi; A S Japp; V Huge; F Schwarz; M F Reiser; T R C Johnson
Journal:  Radiologe       Date:  2012-02       Impact factor: 0.635

Review 2.  Heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

3.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

4.  Scientific considerations in the review and approval of generic enoxaparin in the United States.

Authors:  Sau Lee; Andre Raw; Lawrence Yu; Robert Lionberger; Naiqi Ya; Daniela Verthelyi; Amy Rosenberg; Steve Kozlowski; Keith Webber; Janet Woodcock
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

5.  Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

6.  Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia.

Authors:  Bruce S Sachais; Ann H Rux; Douglas B Cines; Serge V Yarovoi; Lee I Garner; Stephen P Watson; Jillian L Hinds; John J Rux
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

7.  Structural basis for quinine-dependent antibody binding to platelet integrin αIIbβ3.

Authors:  Jianghai Zhu; Jieqing Zhu; Daniel W Bougie; Richard H Aster; Timothy A Springer
Journal:  Blood       Date:  2015-08-17       Impact factor: 22.113

Review 8.  Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).

Authors:  Zheng Cai; Zhiqiang Zhu; Mark I Greene; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2016-03-09       Impact factor: 9.754

Review 9.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

10.  The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution.

Authors:  M R Phillips; A I Khoury; R F Ashton; B A Cairns; A G Charles
Journal:  Anaesth Intensive Care       Date:  2014-01       Impact factor: 1.669

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.